Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
BURLINGTON, Mass. - scPharmaceuticals Inc. (NASDAQ:SCPH), a cardiorenal healthcare company with a market capitalization of $255 million and currently trading at $4.78, announced Thursday it has received five Notices of Allowance from the United States Patent and Trademark Office for patent applications covering its latest furosemide formulation, SCP-111. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 3.85, though it faces profitability challenges.
The pharmaceutical company, which focuses on cardiorenal healthcare, plans to file a supplemental New Drug Application (sNDA) for the SCP-111 formulation this quarter. Once issued, the five patents will join four existing patents owned by the company that cover the same formulation. The company has shown impressive revenue growth of 108% over the last twelve months, with total revenue reaching $50 million.
"These allowances are vital developments in scPharmaceuticals’ pursuit to provide effective care to patients suffering from edema due to heart failure or chronic kidney disease," said John Tucker, Chief Executive Officer of scPharmaceuticals, in a press release statement.
The SCP-111 formulation is designed to treat patients with fluid overload conditions associated with heart failure or chronic kidney disease.
scPharmaceuticals, headquartered in Burlington, Massachusetts, develops treatments for cardiorenal conditions. The company’s current commercial product is FUROSCIX, though specific details about this product were not included in the announcement.
The patent allowances strengthen the company’s intellectual property portfolio as it continues to develop treatments for patients with cardiorenal conditions.
The company noted that its statements regarding future developments, including the anticipated sNDA submission and patent issuances, are subject to various risks and uncertainties that could cause actual results to differ from current expectations. InvestingPro data reveals that analysts have set price targets ranging from $11 to $25, suggesting potential upside, though they’ve recently revised earnings expectations downward. Get deeper insights and access to comprehensive financial analysis with InvestingPro’s detailed research reports, available for over 1,400 US stocks.
In other recent news, SC Pharmaceuticals reported its financial results for the first quarter of 2025, showing a greater loss than analysts had anticipated. The company announced an earnings per share (EPS) of -$0.36, which fell short of the expected -$0.32. Revenue for the quarter was $11.8 million, not meeting the forecasted $12.83 million. These results indicate a revenue shortfall alongside a larger-than-expected loss per share. Despite these financial figures, SC Pharmaceuticals experienced a slight uptick of 0.13% in after-hours trading. The company’s stock had closed down 3.45% during regular trading hours. This recent performance may influence investor sentiment and analyst evaluations moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.